Literature DB >> 12707850

Herpes simplex virus-1 and varicella-zoster virus latency in ganglia.

Bradley M Mitchell1, David C Bloom, Randall J Cohrs, Donald H Gilden, Peter G E Kennedy.   

Abstract

Two human alpha-herpesviruses, herpes simplex virus (HSV)-1 and varicella zoster virus (VZV), account for the most frequent and serious neurologic disease caused by any of the eight human herpesviruses. Both HSV-1 and VZV become latent in ganglia. In this review, the authors describe features of latency for these viruses, such as distribution, prevalence, abundance, and configuration of viral DNA in latently infected human ganglia, as well as transcription, translation, and cell type infected. Studies of viral latency in animal models are also discussed. For each virus, remaining questions and future studies to understand the mechanism of latency are discussed with respect to prevention of serious cutaneous, ocular, and neurologic disease produced by virus reactivation.

Entities:  

Mesh:

Year:  2003        PMID: 12707850     DOI: 10.1080/13550280390194000

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  109 in total

1.  Varicella-Zoster virus gene expression in latently infected rat dorsal root ganglia.

Authors:  P G Kennedy; E Grinfeld; S Bontems; C Sadzot-Delvaux
Journal:  Virology       Date:  2001-10-25       Impact factor: 3.616

2.  Varicella susceptibility and vaccination strategies in young adults.

Authors:  A F Jerant; J S DeGaetano; T D Epperly; A C Hannapel; D R Miller; A J Lloyd
Journal:  J Am Board Fam Pract       Date:  1998 Jul-Aug

3.  A protein encoded by the herpes simplex virus (HSV) type 1 2-kilobase latency-associated transcript is phosphorylated, localized to the nucleus, and overcomes the repression of expression from exogenous promoters when inserted into the quiescent HSV genome.

Authors:  S K Thomas; C E Lilley; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Latent herpes simplex virus in spinal ganglia of mice.

Authors:  J G Stevens; M L Cook
Journal:  Science       Date:  1971-08-27       Impact factor: 47.728

5.  Inducible cyclic AMP early repressor produces reactivation of latent herpes simplex virus type 1 in neurons in vitro.

Authors:  M A Colgin; R L Smith; C L Wilcox
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia.

Authors:  R Mahalingam; M Wellish; W Wolf; A N Dueland; R Cohrs; A Vafai; D Gilden
Journal:  N Engl J Med       Date:  1990-09-06       Impact factor: 91.245

7.  Establishment of a quiescent herpes simplex virus type 1 infection in neurally-differentiated PC12 cells.

Authors:  R J Danaher; R J Jacob; C S Miller
Journal:  J Neurovirol       Date:  1999-06       Impact factor: 2.643

8.  Variation in the structure of varicella-zoster virus DNA.

Authors:  J R Ecker; L Kudler; R W Hyman
Journal:  Intervirology       Date:  1984       Impact factor: 1.763

9.  In situ DNA PCR and RNA hybridization detection of herpes simplex virus sequences in trigeminal ganglia of latently infected mice.

Authors:  A Mehta; J Maggioncalda; O Bagasra; S Thikkavarapu; P Saikumari; T Valyi-Nagy; N W Fraser; T M Block
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

10.  Detection of HSV-1 genome in central nervous system of latently infected mice.

Authors:  D L Rock; N W Fraser
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

View more
  51 in total

1.  Wide variations in herpes simplex virus type 1 inoculum dose and latency-associated transcript expression phenotype do not alter the establishment of latency in the rabbit eye model.

Authors:  J E O'Neil; J M Loutsch; J S Aguilar; J M Hill; E K Wagner; D C Bloom
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 2.  Herpes simplex virus type 1 and Bell's palsy-a current assessment of the controversy.

Authors:  Peter Ge Kennedy
Journal:  J Neurovirol       Date:  2010-02       Impact factor: 2.643

3.  Evidence that the herpes simplex virus type 1 ICP0 protein does not initiate reactivation from latency in vivo.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

4.  Evidence that herpes simplex virus DNA derived from quiescently infected cells in vitro, and latently infected cells in vivo, is physically damaged.

Authors:  Scott Millhouse; Ying-Hsiu Su; Xianchao Zhang; Xiaohe Wang; Benjamin P Song; Li Zhu; Emily Oppenheim; Nigel W Fraser; Timothy M Block
Journal:  J Neurovirol       Date:  2010-10       Impact factor: 2.643

Review 5.  Simian varicella in old world monkeys.

Authors:  Wayne L Gray
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

Review 6.  Latent versus productive infection: the alpha herpesvirus switch.

Authors:  Orkide O Koyuncu; Margaret A MacGibeny; Lynn W Enquist
Journal:  Future Virol       Date:  2018-05-22       Impact factor: 1.831

Review 7.  TLR3 immunity to infection in mice and humans.

Authors:  Shen-Ying Zhang; Melina Herman; Michael J Ciancanelli; Rebeca Pérez de Diego; Vanessa Sancho-Shimizu; Laurent Abel; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2013-01-03       Impact factor: 7.486

Review 8.  Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis.

Authors:  Elena Grebenciucova; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08       Impact factor: 5.081

9.  Array analysis of viral gene transcription during lytic infection of cells in tissue culture with Varicella-Zoster virus.

Authors:  Randall J Cohrs; Michael P Hurley; Donald H Gilden
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  The latency-associated transcript of herpes simplex virus type 1 promotes survival and stimulates axonal regeneration in sympathetic and trigeminal neurons.

Authors:  Mohamed A Hamza; Dennis M Higgins; Lawrence T Feldman; William T Ruyechan
Journal:  J Neurovirol       Date:  2007       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.